Refined list of best practice indicators.
| Indicator | Target |
|---|---|
| 1. Shorten time to diagnosis | |
| Average duration from presentation to HCP to confirmed PsA diagnosis8 | < 6 mos |
| Percent of patients with psoriasis in a year who receive PsA screening tests (clinical or a suitable validated tool such as PEST, CONTEST, or other questionnaire)9 | PsA screening test to be conducted at least once a year |
| 2. Improve multidisciplinary collaboration | |
| Multidisciplinary PsA assessment is available (Y/N)10 | Multidisciplinary collaboration should be available in centers |
| Does the center provide training to increase awareness of symptoms associated with psoriatic disease and train HCP, nurses, etc., to conduct disease assessment?11 | 100% of staff should have followed suitable training on PsA each year |
| 3. Optimize disease management | |
| Average number of evaluations conducted in a year for psoriatic patients who have visited HCP more than once, assessing 6 core domains of PsA: musculoskeletal, skin, function, pain, patient’s global assessment, and quality of life12 | 1–2 evaluations per year to monitor disease activity |
| Percent of new PsA patients who are treated using the T2T strategy or with an agreed treatment goal12 | All patients with new-onset disease should be offered a T2T strategy |
| 4. Improve disease monitoring | |
| Percent of psoriatic disease patients who received full disease assessment at least once every year (e.g., comorbidity index can be leveraged to conduct disease assessment)13 | All patients should have at least an annual assessment for comorbidities |
| Availability of short-term unscheduled appointments for new patients (Y/N)14 | Maximum wait time for unscheduled appointment should be 2 weeks |
HCP: healthcare providers; PsA: psoriatic arthritis; PEST: Psoriasis Epidemiology Screening Tool; CONTEST: CONTEST [study] screening tool; T2T: treat to target.